Glaucoma Treatment Market - Forecasts from 2023 to 2028

The glaucoma treatment market was valued at US$2.047 billion in 2021.

The glaucoma treatment market is anticipated to grow significantly during the forecast period. The term glaucoma refers to a collection of conditions that harm the optic nerve in the eyes. It is the most typical type of optic nerve injury that results in visual loss. Lowering intraocular tension is the major treatment objective. This is accomplished by either decreasing aqueous humour secretion or enhancing drainage. Acute congestive glaucoma, chronic glaucoma, angle-closure glaucoma, and open-angle glaucoma are other categories of glaucoma.

Major growth drivers for the glaucoma treatment market

The increased prevalence of glaucoma, rising healthcare costs, improvements in diagnostic techniques, and favourable reimbursement practices are all contributing to the growth of the glaucoma treatment market. In addition, the availability of novel medication formulations and technical developments in glaucoma therapies, such as minimally invasive glaucoma surgery (MIGS) devices and sustained-release drug delivery systems, are propelling the glaucoma treatment market's expansion.

Increasing prevalence of people suffering from glaucoma

The growing prevalence of glaucoma among people is anticipated to impact the glaucoma treatment market. According to the National Library of Medicine, a higher risk of glaucoma is associated with elderly over 60, family members of those already diagnosed with the condition, steroid users, diabetics, high myopia, hypertension, central corneal thickness less than 5 mm, and ocular trauma. It is projected that 76 million individuals had glaucoma in 2020, and by 2040, the figure is anticipated to rise to 111.8 million.

Growth in the geriatric population is predicted to fuel the market.

The market for glaucoma treatments is greatly boosted by the aging population as age-related factors increase the prevalence of glaucoma, which in turn drives demand for novel medicines and raises healthcare costs associated with eye care. Furthermore, according to a 2017 United Nations report, the prevalence of the disease is predicted to rise in the coming years as the population aged 60 and above rises from 12.7% in 2017 to 21.3% by 2050. A thorough and integrated approach to therapy is required since the senior population frequently experiences various health issues, including the coexistence of glaucoma with other age-related disorders.

Prostaglandin Analogs is anticipated to grow significantly

Prostaglandin analogues, which are essential for controlling intraocular pressure and delaying the onset of the condition, have had a significant effect on the market for glaucoma treatments. The glaucoma pharmaceutical industry has grown as a whole and patient compliance has risen as a result of its widespread usage due to its excellent effectiveness and low adverse effect profile when compared to certain alternatives. Prostaglandin analogues' widespread use has impacted market dynamics and treatment patterns and has fueled glaucoma therapy research and development.

Advancements in technology are predicted to fuel the glaucoma treatment market

Technological advancements in the glaucoma treatment market have revolutionized the landscape, providing innovative solutions for diagnosis, monitoring, and therapeutic interventions. The demand for innovative surgical methods is anticipated to fuel glaucoma treatment market growth. The advancements in medical imaging, optical coherence tomography (OCT), micro-invasive glaucoma surgery (MIGS), selective laser trabeculoplasty (SLT), and progression analysis software further increase the demand for optometrists.

Growing demand for efficient prescription eye drops for glaucoma

Manufacturers and major market participants in the glaucoma treatment market are working to develop innovative medication combinations and prescription eye drops to control glaucoma at an early stage. To ease the burden on healthcare facilities, several biomedical and pharmaceutical companies engage in product development. Several of these medications used to treat glaucoma include beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cholinergic, prostaglandin analogues (PGAs), and certain combination treatments. These drugs assist in reducing intraocular pressure by encouraging fluid evacuation from the patient's eye.

Pipeline therapy is a major market opportunity

The various pipeline therapies for the currently developing disease are the primary drivers of the glaucoma treatment market growth over the forecast period. One such development is a brand-new medicine for the treatment of glaucoma that was developed by the Institute for Therapeutics Discovery & Development (ITDD) and the Department of Medicinal Chemistry at the University of Minnesota College of Pharmacy. The leading glaucoma drugs in development were latanoprost, ripasudil hydrochloride hydrate, PH-011, PH-012, netarsudil mesylate, latanoprost, (bimatoprost + timolol), and (latanoprost + netarsudil).

North America is anticipated to show significant growth in the market

One of the main factors contributing to North America's glaucoma treatment market growth is its sophisticated hospital diagnosis infrastructure and efficient treatment framework. Furthermore, the growth is being supported by the increasing number of FDA approvals and medicine launches for the treatment in the area.

Market Key Developments

• In April 2023, new novel gene therapy for glaucoma was developed by Trinity College geneticists.
• In July 2022, AbbVie and iSTAR Medical formed a strategic agreement to commercialise the MINIject® device, a less invasive glaucoma surgical tool for glaucoma patients.
• In April 2022, to carry out the Phase 1 study for SBI-100 Ophthalmic Emulsion, Skye Bioscience chose CMAX clinical research. Skye got assistance from CMAX, one of the most renowned trial operators in the world which specialises in early-phase studies.

Segmentation:

By Disease Type

• Open Angle Glaucoma
• Angle Closure Glaucoma
• Others

By Drug Class

• Prostaglandins Analogs
• Beta-blockers
• Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others